Tang-Liu D D, Shackleton M, Richman J B
Department of Pharmacokinetics, Allergan, Inc., Irvine, California.
J Ocul Pharmacol. 1988 Fall;4(3):269-78. doi: 10.1089/jop.1988.4.269.
Dihydrobunolol is an ocular metabolite equipotent to levobunolol. In order to understand the formation and distribution of dihydrobunolol after an ophthalmic dose of levobunolol, studies in vitro and in vivo were initiated. The metabolism of levobunolol to dihydrobunolol was investigated using an organ-culture technique. The corneal formation of dihydrobunolol was pH-dependent and increased as the pH of the incubation fluid increased from 5.3 to 8.3. Its formation from levobunolol was saturable with Vmax and Km values (pH 7.4) of 13.2 nmol/min/gm of cornea and 1.48 mM, respectively. After a topical dose of 0.5% levobunolol hydrochloride to rabbit eyes, rapid absorption of levobunolol and facila formation of dihydrobunolol were noted. The drug concentration in the eye drop (approximately 17 mM) was much higher than Km and would saturate the epithelial reductase system in the cornea during drug absorption. The total concentrations of levobunolol and dihydrobunolol in ocular tissues were in the micromolar range throughout the experimental period. Dihydrobunolol, after distribution equilibrium, was the major drug-derived species in the cornea, aqueous humor, and iris-ciliary body. The study results indicated pH-dependent and capacity-limited formation of dihydrobunolol in the cornea. Buffering capacity and the drug concentration in the ophthalmic dose are important formulation strategies because they may affect the rate and the extent of dihydrobunolol formation in the epithelial cell layers of the cornea.
二氢布诺洛尔是一种与左布诺洛尔等效的眼部代谢产物。为了解眼部给予左布诺洛尔后二氢布诺洛尔的形成和分布情况,开展了体外和体内研究。采用器官培养技术研究了左布诺洛尔向二氢布诺洛尔的代谢过程。二氢布诺洛尔在角膜中的形成过程依赖于pH值,随着培养液pH值从5.3升至8.3,其形成量增加。其由左布诺洛尔形成的过程具有饱和性,在pH 7.4时,Vmax和Km值分别为13.2 nmol/(min·g角膜)和1.48 mM。给兔眼局部滴注0.5%盐酸左布诺洛尔后,观察到左布诺洛尔迅速吸收且二氢布诺洛尔易于形成。滴眼液中的药物浓度(约17 mM)远高于Km值,在药物吸收过程中会使角膜中的上皮还原酶系统饱和。在整个实验期间,眼部组织中左布诺洛尔和二氢布诺洛尔的总浓度处于微摩尔范围内。分布平衡后,二氢布诺洛尔是角膜、房水和虹膜睫状体中主要的药物衍生成分。研究结果表明,角膜中二氢布诺洛尔的形成过程依赖于pH值且具有容量限制。缓冲能力和眼科制剂中的药物浓度是重要的制剂策略,因为它们可能会影响角膜上皮细胞层中二氢布诺洛尔的形成速率和程度。